DrugPatentWatch Database Preview
NAVANE Drug Profile
see a sample report or, see our see our flat-rate plans
When do Navane patents expire, and when can generic versions of Navane launch?
The generic ingredient in NAVANE is thiothixene hydrochloride. There are six drug master file entries for this compound. Additional details are available on the thiothixene hydrochloride profile page.
Summary for NAVANE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Bulk Api Vendors: | 34 |
| Patent Applications: | 2,933 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | NAVANE at DailyMed |
Synonyms for NAVANE
| (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide |
| (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide |
| (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide |
| (E)-Thiothixene |
| (Z)-N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulfonamide |
| (Z)-Thiothixene |
| {2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene |
| 2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene |
| 3313-26-6 |
| 5591-45-7 |
| 7318FJ13YJ |
| 9H-Thioxanthene-2-sulfonamide, N, {N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-,} (Z)- |
| 9H-Thioxanthene-2-sulfonamide, N,N-dimethyl-9-[3-(4-methyl- 1-piperazinyl)propylidene]-, (9Z)- |
| 9H-Thioxanthene-2-sulfonamide, N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]- |
| AC1LJ0FG |
| AK397466 |
| AKOS015850761 |
| AN-18958 |
| AOB5787 |
| AS-16925 |
| BDBM78576 |
| BIDD:PXR0153 |
| CCG-205218 |
| CHEBI:9571 |
| CHEMBL1201 |
| cid_941651 |
| cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide |
| cis-Thiothixene |
| CP 12252-1 |
| CP-12,252-1 |
| CP-12,252-1 base |
| CPD000058396 |
| CS-7959 |
| D00374 |
| D0E0LQ |
| DB01623 |
| DTXSID2091542 |
| GFBKORZTTCHDGY-UWVJOHFNSA-N |
| GTPL212 |
| HMS2230F08 |
| HY-108324 |
| Lopac0_001144 |
| LS-153666 |
| LS-153667 |
| MFCD00079574 |
| MLS000028463 |
| MLS006010662 |
| N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thiaxanthene-2-sulfonamide |
| N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide |
| N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide |
| N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-9H-thioxanthene-2-sulfonamide # |
| N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide |
| N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide |
| N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide |
| Navan |
| Navane (TN) |
| Navaron |
| NCGC00162353-01 |
| NSC-108165 |
| NSC108165 |
| Opera_ID_626 |
| Orbinamon |
| P 4657B |
| P-4657 B |
| P-4657-B |
| P-4657A |
| P-4657B |
| PDSP1_000038 |
| PDSP1_000625 |
| PDSP1_000626 |
| PDSP2_000038 |
| PDSP2_000622 |
| PL001477 |
| SAM002589997 |
| SCHEMBL34305 |
| SMR000058396 |
| T15560 |
| thiothixene |
| Thiothixene (USP) |
| Thiothixene (Z) |
| Thiothixene [USAN:BAN] |
| THIOTHIXENE HCL |
| Thiothixene hydrochloride |
| Thiothixene Hydrochloride (base) |
| Thiothixene, meets USP testing specifications |
| Thiothixene, United States Pharmacopeia (USP) Reference Standard |
| Thiothixine |
| Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)- |
| Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)-, (E)- |
| Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)-, (Z)- |
| Tiotixene |
| Tiotixene (JAN) |
| Tiotixeno |
| Tiotixeno [INN-Spanish] |
| Tiotixenum |
| Tiotixenum [INN-Latin] |
| trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide |
| UNII-7318FJ13YJ |
| UNII-LF886533UR component GFBKORZTTCHDGY-UWVJOHFNSA-N |
| ZINC30690433 |
US Patents and Regulatory Information for NAVANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | NAVANE | thiothixene | CAPSULE;ORAL | 016584-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pfizer | NAVANE | thiothixene hydrochloride | INJECTABLE;INJECTION | 016904-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pfizer | NAVANE | thiothixene | CAPSULE;ORAL | 016584-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pfizer | NAVANE | thiothixene hydrochloride | INJECTABLE;INJECTION | 016904-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
